Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes

Studies with cDNA and oligonucleotide expression arrays

James M. Rae, Michael D. Johnson, Marc E. Lippman, David A. Flockhart

Research output: Contribution to journalArticle

250 Citations (Scopus)

Abstract

We used expression microarrays to test the effects of rifampin on the overall pattern of mRNA expression of multiple metabolic enzymes in primary human hepatocytes. Two microarrays were utilized, a cDNA-based array and one that is oligonucleotide-based. The cDNA-based expression arrays showed that rifampin caused a 7.7 ± 6.6-fold induction in CYP2A6 and a 4.0 ± 2.0-fold increase in the CYP2C family of enzymes while having little effect on CYP2E1 or CYP2D6. Many non-P450 enzymes were also induced including FMO-4 and -5, UGT-1A, MAO-B, and GST-P1. The oligonucleotide-based array made it possible to detect different levels of induction within the CYP2C family, with rifampin causing a 6.5-fold increase in expression of CYP2C8 and a 3.7-fold increase in CYP2C9 while having no effect on the level of CYP2C18 mRNA. Rifampin also induced other CYP enzymes including CYP2B6 and all three members of the CYP3A family, with CYP3A4 showing the highest level of induction at 55.1-fold. RNase protection assays were used to validate results from the arrays and a comparison of all three methods of mRNA detection showed qualitatively similar results. These data make it clear that rifampin treatment brings about broad changes in the pattern of gene expression, rather than increased expression of a small number of metabolic enzymes. Clinicians and researchers who use and study rifampin and other drugs that induce drug metabolism should be alert to the possibility of multiple effects.

Original languageEnglish (US)
Pages (from-to)849-857
Number of pages9
JournalJournal of Pharmacology and Experimental Therapeutics
Volume299
Issue number3
StatePublished - 2001
Externally publishedYes

Fingerprint

Rifampin
Oligonucleotide Array Sequence Analysis
Hepatocytes
Complementary DNA
Pharmaceutical Preparations
Genes
Enzymes
Cytochrome P-450 CYP3A
Messenger RNA
Cytochrome P-450 CYP2E1
Cytochrome P-450 CYP2D6
Monoamine Oxidase
Ribonucleases
Oligonucleotides
Research Personnel
Gene Expression

ASJC Scopus subject areas

  • Pharmacology

Cite this

Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes : Studies with cDNA and oligonucleotide expression arrays. / Rae, James M.; Johnson, Michael D.; Lippman, Marc E.; Flockhart, David A.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 299, No. 3, 2001, p. 849-857.

Research output: Contribution to journalArticle

@article{6f941bd75d1440cf88543335dc43b051,
title = "Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: Studies with cDNA and oligonucleotide expression arrays",
abstract = "We used expression microarrays to test the effects of rifampin on the overall pattern of mRNA expression of multiple metabolic enzymes in primary human hepatocytes. Two microarrays were utilized, a cDNA-based array and one that is oligonucleotide-based. The cDNA-based expression arrays showed that rifampin caused a 7.7 ± 6.6-fold induction in CYP2A6 and a 4.0 ± 2.0-fold increase in the CYP2C family of enzymes while having little effect on CYP2E1 or CYP2D6. Many non-P450 enzymes were also induced including FMO-4 and -5, UGT-1A, MAO-B, and GST-P1. The oligonucleotide-based array made it possible to detect different levels of induction within the CYP2C family, with rifampin causing a 6.5-fold increase in expression of CYP2C8 and a 3.7-fold increase in CYP2C9 while having no effect on the level of CYP2C18 mRNA. Rifampin also induced other CYP enzymes including CYP2B6 and all three members of the CYP3A family, with CYP3A4 showing the highest level of induction at 55.1-fold. RNase protection assays were used to validate results from the arrays and a comparison of all three methods of mRNA detection showed qualitatively similar results. These data make it clear that rifampin treatment brings about broad changes in the pattern of gene expression, rather than increased expression of a small number of metabolic enzymes. Clinicians and researchers who use and study rifampin and other drugs that induce drug metabolism should be alert to the possibility of multiple effects.",
author = "Rae, {James M.} and Johnson, {Michael D.} and Lippman, {Marc E.} and Flockhart, {David A.}",
year = "2001",
language = "English (US)",
volume = "299",
pages = "849--857",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes

T2 - Studies with cDNA and oligonucleotide expression arrays

AU - Rae, James M.

AU - Johnson, Michael D.

AU - Lippman, Marc E.

AU - Flockhart, David A.

PY - 2001

Y1 - 2001

N2 - We used expression microarrays to test the effects of rifampin on the overall pattern of mRNA expression of multiple metabolic enzymes in primary human hepatocytes. Two microarrays were utilized, a cDNA-based array and one that is oligonucleotide-based. The cDNA-based expression arrays showed that rifampin caused a 7.7 ± 6.6-fold induction in CYP2A6 and a 4.0 ± 2.0-fold increase in the CYP2C family of enzymes while having little effect on CYP2E1 or CYP2D6. Many non-P450 enzymes were also induced including FMO-4 and -5, UGT-1A, MAO-B, and GST-P1. The oligonucleotide-based array made it possible to detect different levels of induction within the CYP2C family, with rifampin causing a 6.5-fold increase in expression of CYP2C8 and a 3.7-fold increase in CYP2C9 while having no effect on the level of CYP2C18 mRNA. Rifampin also induced other CYP enzymes including CYP2B6 and all three members of the CYP3A family, with CYP3A4 showing the highest level of induction at 55.1-fold. RNase protection assays were used to validate results from the arrays and a comparison of all three methods of mRNA detection showed qualitatively similar results. These data make it clear that rifampin treatment brings about broad changes in the pattern of gene expression, rather than increased expression of a small number of metabolic enzymes. Clinicians and researchers who use and study rifampin and other drugs that induce drug metabolism should be alert to the possibility of multiple effects.

AB - We used expression microarrays to test the effects of rifampin on the overall pattern of mRNA expression of multiple metabolic enzymes in primary human hepatocytes. Two microarrays were utilized, a cDNA-based array and one that is oligonucleotide-based. The cDNA-based expression arrays showed that rifampin caused a 7.7 ± 6.6-fold induction in CYP2A6 and a 4.0 ± 2.0-fold increase in the CYP2C family of enzymes while having little effect on CYP2E1 or CYP2D6. Many non-P450 enzymes were also induced including FMO-4 and -5, UGT-1A, MAO-B, and GST-P1. The oligonucleotide-based array made it possible to detect different levels of induction within the CYP2C family, with rifampin causing a 6.5-fold increase in expression of CYP2C8 and a 3.7-fold increase in CYP2C9 while having no effect on the level of CYP2C18 mRNA. Rifampin also induced other CYP enzymes including CYP2B6 and all three members of the CYP3A family, with CYP3A4 showing the highest level of induction at 55.1-fold. RNase protection assays were used to validate results from the arrays and a comparison of all three methods of mRNA detection showed qualitatively similar results. These data make it clear that rifampin treatment brings about broad changes in the pattern of gene expression, rather than increased expression of a small number of metabolic enzymes. Clinicians and researchers who use and study rifampin and other drugs that induce drug metabolism should be alert to the possibility of multiple effects.

UR - http://www.scopus.com/inward/record.url?scp=0035201366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035201366&partnerID=8YFLogxK

M3 - Article

VL - 299

SP - 849

EP - 857

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -